HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term 3,5,3'-triiodothyroacetic acid therapy in a child with hyperthyroidism caused by thyroid hormone resistance: pharmacological study and therapeutic recommendations.

AbstractBACKGROUND:
The effectiveness of short-term 3,5,3'-triiodothyroacetic acid (TRIAC) therapy for the treatment of hyperthyroidism caused by thyroid hormone resistance (RTH) has been documented. Here, we report a 3-year course of TRIAC therapy in an RTH boy, with a quantitative evaluation of the therapeutic effects and pharmacological study of TRIAC.
PATIENT FINDINGS:
The gene encoding the thyroid hormone receptor beta (THRB) of the patient carries a P453T mutation. During treatment with up to 3.0 mg TRIAC per day, reduction in the thyroid volume, resolution of supraventricular arrhythmia, and decrease in thyroid-stimulating hormone (TSH) and free-thyroxine (FT4) levels were achieved. In addition, attention-deficit hyperactivity disorder (ADHD) symptoms improved, with a concomitant decline in the ADHD Rating Scale score.
SUMMARY:
A TRIAC pharmacokinetic study, conducted using triiodothyronine level as a surrogate for TRIAC level, demonstrated that TRIAC disappears from the circulation rapidly and has a shorter duration of TSH secretion inhibitory effect in the RTH patient compared to that in the control subject. Studies of TSH and FT4 levels over a period of 3 years indicated that the TRIAC effect is dose dependent.
CONCLUSIONS:
TRIAC was effective and safe in ameliorating the effects of hyperthyroidism and ADHD symptoms in a child with known genetic RTH. Further, it was demonstrated that TRIAC has a short half-life and functions dose dependently.
AuthorsRie Anzai, Masanori Adachi, Noriko Sho, Koji Muroya, Yumi Asakura, Kazumichi Onigata
JournalThyroid : official journal of the American Thyroid Association (Thyroid) Vol. 22 Issue 10 Pg. 1069-75 (Oct 2012) ISSN: 1557-9077 [Electronic] United States
PMID22947347 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Thyroid Hormone Receptors beta
  • Triiodothyronine
  • 3,3',5-triiodothyroacetic acid
  • Thyrotropin
  • Thyroxine
Topics
  • Adolescent
  • Adult
  • Atrial Premature Complexes (drug therapy)
  • Attention Deficit Disorder with Hyperactivity (drug therapy)
  • Child
  • Child, Preschool
  • Female
  • Half-Life
  • Humans
  • Hyperthyroidism (drug therapy)
  • Male
  • Thyroid Hormone Receptors beta (genetics)
  • Thyroid Hormone Resistance Syndrome (drug therapy)
  • Thyrotropin (blood)
  • Thyroxine (blood)
  • Triiodothyronine (administration & dosage, analogs & derivatives, blood, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: